Administration of 4-(<i>α</i>-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1<sup>G93A</sup> Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis

<div>iNOS formation and MMP-9 expression. Immunohistochemical (IHC) detection of iNOS tissue expression reveals that untreated SOD1tg rats have a positive staining for this marker (a), while there is an absence of positivity in brain sections sampled from GMG-ITC treated SOD1tg rats (b). By IHC stain, brain sections sampled from untreated SOD1tg rats exhibit positive staining for MMP-9 (c), whereas brain sections obtained from GMG-ITC treated SOD1tg rats do not stain for MMP-9 (d).</div>

BioMed Research International

fig8

Figure 8

Figure 8: Administration of 4-(<i>α</i>-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1<sup>G93A</sup> Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis 

Figure 8 | Administration of 4-(α-L-Rhamnosyloxy)-benzyl Isothiocyanate Delays Disease Phenotype in SOD1G93A Rats: A Transgenic Model of Amyotrophic Lateral Sclerosis 